Early atrophy of pallidum and accumbens nucleus in Huntington’s disease

In Huntington’s disease (HD) atrophy of the caudate nucleus and putamen has been described many years before clinical manifestation. Volume changes of the pallidum, thalamus, brainstem, accumbens nucleus, hippocampus, and amygdala are less well investigated, or reported with contradicting results. The aim of our study is to provide a more precise view of the specific atrophy of the subcortical grey matter structures in different stages of Huntington’s disease, and secondly to investigate how this influences the clinical manifestations. All TRACK-HD subjects underwent standardised T1-weighted 3T MRI scans encompassing 123 manifest HD (stage 1, n = 77; stage 2, n = 46), 120 premanifest HD (close to onset n = 58, far from onset n = 62) and 123 controls. Using FMRIB’s FIRST and SIENAX tools the accumbens nucleus, amygdala, brainstem, caudate nucleus, hippocampus, pallidum, putamen, thalamus and whole brain volume were extracted. Results showed that volumes of the caudate nucleus and putamen were reduced in premanifest HD far from predicted onset (>10.8 years). Atrophy of accumbens nucleus and pallidum was apparent in premanifest HD in the close to onset group (0–10.8 years). All other structures were affected to some degree in the manifest group, although brainstem, thalamus and amygdala were relatively spared. The accumbens nucleus, putamen, pallidum and hippocampus had a strong significant correlation with functional and motor scores. We conclude that volume changes may be a sensitive and reliable measure for early disease detection and in this way serve as a biomarker for Huntington’s disease. Besides the caudate nucleus and putamen, the pallidum and the accumbens nucleus show great potential in this respect.

[1]  Jane S. Paulsen,et al.  A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length , 2004, Clinical genetics.

[2]  A. Dale,et al.  Regional and progressive thinning of the cortical ribbon in Huntington’s disease , 2002, Neurology.

[3]  J. Brandt,et al.  Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at‐risk persons , 1994, Neurology.

[4]  Mark W. Woolrich,et al.  Advances in functional and structural MR image analysis and implementation as FSL , 2004, NeuroImage.

[5]  Nick C Fox,et al.  Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data , 2009, The Lancet Neurology.

[6]  G. Pearlson,et al.  Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. , 1996, Archives of neurology.

[7]  M. MacDonald,et al.  CAG repeat number governs the development rate of pathology in Huntington's disease , 1997, Annals of neurology.

[8]  J. Brandt,et al.  When does Huntington's disease begin? , 1998, Journal of the International Neuropsychological Society.

[9]  R. Dom,et al.  Neuropathology of Huntington's chorea , 1976, Neurology.

[10]  Stephen M. Smith,et al.  Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis , 2002, NeuroImage.

[11]  Stephen M. Smith,et al.  Bayesian statistical models of shape and appearance for subcortical brain segmentation , 2007 .

[12]  J. Caboche,et al.  Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments , 2008, Current opinion in neurology.

[13]  G. Pearlson,et al.  Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[14]  L. Bäckman,et al.  Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. , 1997, Brain : a journal of neurology.

[15]  Mark Mühlau,et al.  Striatal gray matter loss in Huntington's disease is leftward biased , 2007, Movement disorders : official journal of the Movement Disorder Society.

[16]  F. Cendes,et al.  Striatal and extrastriatal atrophy in Huntington's disease and its relationship with length of the CAG repeat. , 2006, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[17]  Jane S. Paulsen,et al.  Detection of Huntington’s disease decades before diagnosis: the Predict-HD study , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[18]  Jan Kassubek,et al.  Thalamic atrophy in Huntington's disease co-varies with cognitive performance: a morphometric MRI analysis. , 2005, Cerebral cortex.

[19]  J Kassubek,et al.  Topography of cerebral atrophy in early Huntington’s disease: a voxel based morphometric MRI study , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[20]  Jane S. Paulsen,et al.  Preparing for preventive clinical trials: the Predict-HD study. , 2006, Archives of neurology.

[21]  L. Massieu,et al.  Excitotoxic neuronal death and the pathogenesis of Huntington's disease. , 2008, Archives of Medical Research.

[22]  Terry L. Jernigan,et al.  Cerebral structure on MRI, part II: Specific changes in Alzheimer's and Huntington's diseases , 1991, Biological Psychiatry.

[23]  Jane S. Paulsen,et al.  CAG‐repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[24]  R. Roos,et al.  Basal ganglia volume and clinical correlates in ‘preclinical’ Huntington’s disease , 2008, Journal of Neurology.

[25]  S. Fahn,et al.  Huntington disease , 1979, Neurology.

[26]  C D Good,et al.  The distribution of structural neuropathology in pre-clinical Huntington's disease. , 2002, Brain : a journal of neurology.

[27]  F Cendes,et al.  Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[28]  S. Folstein,et al.  Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease , 1992, Annals of neurology.

[29]  J. Brandt,et al.  Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. , 1999, Brain : a journal of neurology.

[30]  Jan Kassubek,et al.  Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: A neuropsychological and voxel-based morphometric study , 2005, Journal of the Neurological Sciences.

[31]  N Makris,et al.  Evidence for more widespread cerebral pathology in early HD , 2003, Neurology.

[32]  J. Ashburner,et al.  Progression of structural neuropathology in preclinical Huntington’s disease: a tensor based morphometry study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[33]  J. Brandt,et al.  Onset and rate of striatal atrophy in preclinical Huntington disease , 2004, Neurology.

[34]  Elizabeth H. Aylward,et al.  Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease , 2007, Brain Research Bulletin.

[35]  Nick C Fox,et al.  Increased rate of whole-brain atrophy over 6 months in early Huntington disease , 2006, Neurology.

[36]  Anne-Catherine Bachoud-Lévi,et al.  Distribution of grey matter atrophy in Huntington’s disease patients: A combined ROI-based and voxel-based morphometric study , 2006, NeuroImage.

[37]  B Fischl,et al.  Regional cortical thinning in preclinical Huntington disease and its relationship to cognition , 2005, Neurology.

[38]  P. Matthews,et al.  Normalized Accurate Measurement of Longitudinal Brain Change , 2001, Journal of computer assisted tomography.